Treatment of T-cell large granular lymphocytic leukemia when first-line methotrexate or cyclophosphamide has not achieved haematological response

This protocol covers the next step in managing T-cell large granular lymphocytic leukemia (T-LGL leukemia) in patients who have completed first-line immunosuppressive therapy without achieving adequate improvement in cytopenias.

Prior line — failure condition

First-line immunosuppression — either weekly methotrexate, or low-dose cyclophosphamide given for a fixed duration of up to one year — did not achieve the target of amelioration of the cytopenias (haematological response). Because the median time to response with these agents is 3–4 months, response is formally assessed at around month 4 before escalation is considered.

Next-line approach & goals

After failure of first-line therapy, an established immunosuppressive agent is used as the next step. The treatment goal remains amelioration of the cytopenias, with a median time to response of 3–4 months again expected. The complete protocol — including the specific agent, sequencing, and response assessment criteria — is available in full below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/hon.70076

For many years, the standard of care has been immunosuppression, with weekly methotrexate, low dose cyclophosphamide and ciclosporin remaining the first to third line treatments for most clinicians.

Median time to response with these agents is 3–4 months and therefore it is important not to terminate the treatment too early because of lack of efficacy.

View source ↗